Table 2 Frequencies of dominant CXCL12 genotypes and haplotypes with results from comparing these frequencies between seroconvertors (HIV+) and high-risk exposed uninfected participants (HIV−)
From: Haplotype analysis of the SDF-1 (CXCL12) gene in a longitudinal HIV-1/AIDS cohort study
SNP | African Americans | European Americans | ||||||
---|---|---|---|---|---|---|---|---|
HIV+ | HIV− | OR (95% CI) | P | HIV+ | HIV− | OR (95% CI) | P | |
(n=294) | (n=81) | (n=668) | (n=145) | |||||
Dominant genotype frequencies | ||||||||
rs754618 | 0.193 | 0.173 | 1.15 (0.60–2.18) | 0.76 | 0.543 | 0.441 | 1.50 (1.05–2.16) | 0.03 |
rs17156287 | 0.082 | 0.077 | 1.07 (0.42–2.72) | 1.00 | 0.168 | 0.140 | 1.25 (0.74–2.11) | 0.45 |
ss46566436 | — | —% | — | — | 0.069 | 0.056 | 1.23 (0.54–2.79) | 0.84 |
rs2839693 | 0.455 | 0.462 | 0.96 (0.59–1.60) | 0.90 | 0.279 | 0.268 | 1.06 (0.70–1.60) | 0.84 |
rs266085 | 0.409 | 0.449 | 0.85 (0.48–1.45) | 0.61 | 0.585 | 0.674 | 0.68 (0.46–1.01) | 0.06 |
rs2297630 | 0.107 | 0.082 | 1.33 (0.53–3.33) | 0.67 | 0.467 | 0.401 | 1.30 (0.89–1.92) | 0.21 |
rs1801157 | 0.125 | 0.148 | 0.82 (0.40–1.83) | 0.58 | 0.376 | 0.490 | 0.63 (0.44–0.90) | 0.01 |
rs1801157− | 0.003 | 0.025 | 0.13 (0–2.56) | 0.11 | 0.038 | 0.052 | 0.72 (0.31–1.86) | 0.38 |
recessive* | ||||||||
rs2522 | 0.160 | 0.187 | 0.83 (0.42–1.75) | 0.60 | 0.064 | 0.052 | 1.25 (0.54–3.33) | 0.70 |
rs1065297 | 0.217 | 0.205 | 1.08 (0.56–2.14) | 0.88 | 0.066 | 0.054 | 1.23 (0.56–3.09) | 0.72 |
Dominant haplotype frequencies | ||||||||
Haplotype I | 0.532 | 0.553 | 0.93 (0.55–1.56) | 0.79 | 0.357 | 0.420 | 0.77 (0.52–1.16) | 0.21 |
Haplotype III | 0.161 | 0.145 | 1.15 (0.56–2.38) | 0.71 | 0.023 | 0.050 | 0.42 (0.16–1.16) | 0.08 |
Haplotype VII | 0.066 | 0.118 | 0.54 (0.23–1.26) | 0.15 | 0.023 | 0.025 | 0.95 (0.26–3.40) | 0.94 |